Specific Plasma Autoantibody Reactivity in Myelodysplastic Syndromes | Aplastic Anemia and MDS International Foundation

Specific Plasma Autoantibody Reactivity in Myelodysplastic Syndromes

Journal Title: 
Sci Rep
Author(s): 
Mias GI, Chen R, Zhang Y, Sridhar K, Sharon D, Xiao L, Im H, Snyder MP, Greenberg PL
Primary Author: 
Mias GI
Original Publication Date: 
Friday, November 22, 2013

Increased autoantibody reactivity in plasma from Myelodysplastic Syndromes (MDS) patients may provide novel disease signatures, and possible early detection. In a two-stage study we investigated Immunoglobulin G reactivity in plasma from MDS, Acute Myeloid Leukemia post MDS patients, and a healthy cohort. In exploratory Stage I we utilized high-throughput protein arrays to identify 35 high-interest proteins showing increased reactivity in patient subgroups compared to healthy controls. In validation Stage II we designed new arrays focusing on 25 of the proteins identified in Stage I and expanded the initial cohort. We validated increased antibody reactivity against AKT3, FCGR3A and ARL8B in patients, which enabled sample classification into stable MDS and healthy individuals. We also detected elevated AKT3 protein levels in MDS patient plasma. The discovery of increased specific autoantibody reactivity in MDS patients, provides molecular signatures for classification, supplementing existing risk categorizations, and may enhance diagnostic and prognostic capabilities for MDS.

Bone Marrow Diseases: